Abstract 251P
Background
According to data of Globocan 2018 year, 18.1 million of new cancer cases have been registered and more than half of these cases occur in the Asian continent. Moreover, among women, cervical cancer takes the 4th place in morbidity and mortality. In the Republic of Uzbekistan cervical cancer takes third place among all cancers. Thus, remaining one of the frequent oncogynecological pathology, cervical cancer is a serious public health problem both in the world and in Uzbekistan.
Methods
To analyze condition of morbidity and mortality of cervical cancer we studied the state report -Information on diseases of malignant neoplasms.
Results
The average age of patients with cervical cancer was 61.3 in 2009 y, and 58.3 in 2019y. In 2009 y, the incidence rate per 100,000 population was 4.6, and in 2019 y this indicator increased to 5.6. Moreover, the highest incidence rate per 100,000 population in 2009 was observed in the Republic of Karakalpakstan, Tashkent city, Namangan, Andijan and Khorezm regions with indicators of 7.3; 7.0; 6.3; 5.8 and 5.7 per 100,000 population respectively, and the lowest in Surkhandarya (2.2), Kashkadarya (2.8) and Jizzakh (3.2) regions. In comparison of 2019 y, the highest incidence rate per 100,000 population was in Tashkent, the Republic of Karakalpakstan, Namangan and Khorezm regions with indicators of 11.8; 7.3; 6.8 and 6.5, respectively, and the lowest was observed in Kashkadarya (4.3), Samarkand (3.7) and Surkhandarya (2.8) regions. According to mortality rates, it was showed that there was growth of this indicator from 2.0 per 100,000 population in 2009 y to 3.0 per 100,000 population in 2019 y. Relatively high mortality rate per 100,000 population in 2009 y was observed in Tashkent (4.2), Khorezm (3.4) and Tashkent (2.9) regions, and in 2019 in the Republic of Karakalpakistan, Namangan and Khorezm regions with indicators of 5.8; 5.1 and 4.8, respectively.
Conclusions
In conclusion it can be shown that cervical cancer has a tendency to increase both morbidity and mortality in the Republic of Uzbekistan. The increase in morbidity is due to the intensive work of primary medical care, implementation of modern diagnostic methods, creation and use of diagnostic and treatment standards, and screening programs.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session